Connor, Clark & Lunn Investment Management Ltd. Solid Biosciences Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.51 - $7.56 $5,514 - $81,738	10,812 New	10,812 $5,000
Q2 2022 Aug 05, 2022	SELL	$0.43 - $1.24 $9,030 - $26,041	-21,001 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.74 - $1.79 $88,270 - $213,518	-119,284 Reduced 85.03%	21,001 $25,000
Q4 2021 Feb 10, 2022	BUY	$1.69 - $2.46 $88,679 - $129,083	52,473 Added 59.76%	140,285 $245,000
Q3 2021 Nov 12, 2021	BUY	$2.38 - $3.77 $132,582 - $210,015	55,707 Added 173.52%	87,812 $210,000
Q2 2021 Aug 12, 2021	SELL	$3.49 - $5.51 $186,086 - $293,793	-53,320 Reduced 62.42%	32,105 $118,000
Q1 2021 May 13, 2021	BUY	$5.37 - $10.72 $458,732 - $915,756	85,425 New	85,425 $472,000

Others Institutions Holding SLDB

# of Institutions

Shares Held

Call Options Held

Put Options Held

View Full List

About Solid Biosciences Inc.

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $53.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

More about SLDB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account